Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
IN RE: Intercept Pharmaceuticals, Inc. Securities Litigation
Case Number:
1:14-cv-01123
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
May 06, 2016
Intercept To Pay $55M To End Investors' Stock-Drop MDL
Intercept Pharmaceuticals Inc. will fork over $55 million to resolve multidistrict litigation brought by investors accusing it of securities fraud by concealing a liver drug's side effects, according to a stipulation filed Thursday in New York federal court.
-
March 05, 2015
Intercept Can't Dodge Investors' Stock Drop MDL
A New York federal judge on Wednesday refused to dismiss multidistrict litigation brought by investors accusing Intercept Pharmaceuticals Inc. of securities fraud, finding the investors provided evidence that the company and its executives knowingly concealed a liver drug's side effects.